Alder Biopharmaceuticals Inc. (ALDR)

Oncology Corporate Profile

Stock Performance

28.1300
0.2700

HQ Location

11804 North Creek Parkway South
Bothell, WA 98011

Company Description

Alder Biopharmaceuticals Inc. uniquely identifies, develops and manufactures novel antibody therapeutics to alleviate human suffering in cancer, pain, cardiovascular and autoimmune and inflammatory disease areas. Alder's management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics and enabling partners through the out-licensing of its technologies.

Website: http://www.alderbio.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
BMS-945429 (formerly ALD518)interleukin-6 monoclonal antibodySupportive CareIIBristol-Myers Squibb

View additional information on product candidates here »

Source


http://www.alderbio.com/

Recent News Headlines

Alder BioPharmaceuticals Announces Presentations at 69th Annual American Academy of Neurology Meeting Supporting Development of Eptinezumab for Migraine Prevention

3/6/2017 01:00 pm

[GlobeNewswire] - BOTHELL, Wash., March 06, 2017-- Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that data for eptinezumab, which ...

Alder BioPharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial and Operating Results

2/23/2017 09:01 pm

[GlobeNewswire] - 2016 Clinical Data Support Eptinezumab’ s Potential to Deliver a Unique Combination of Speed to Clinical Benefit and Effectiveness That Persists for at Least Three Months After a Single Administration. ...

Alder BioPharmaceuticals to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial and Operating Results

2/16/2017 01:00 pm

[GlobeNewswire] - BOTHELL, Wash., Feb. 16, 2017-- Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will report its fourth quarter ...

Alder BioPharmaceuticals to Present at the Leerink Partners 6th Annual Global Healthcare Conference

2/9/2017 01:00 pm

[GlobeNewswire] - BOTHELL, Wash., Feb. 09, 2017-- Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation ...

Alder BioPharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference

1/2/2017 01:00 pm

[GlobeNewswire] - BOTHELL, Wash., Jan. 02, 2017-- Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation ...

The Extraordinary General Shareholders’ Meeting of 22 December 2016 marks a new phase in the Group’s development plan

12/29/2016 10:05 am

[at noodls] - Delta Drone held an Extraordinary General Shareholders' meeting today pursuant to a second notice of meeting. 5,401,881 shares representing 20.62% of the total number of shares were present or represented, ...

Subscription of one block of 1 million euros under the February 2015 contract for convertible notes with attached warrants

12/21/2016 08:02 pm

[at noodls] - Consolidated net assets per share * Before the issue of a maximum of 1,995,980 new shares resulting from (i) the conversion of the 100 OCA and (ii) the exercise of the 991,080 BSA €0.37 After the issue ...